erythromycin ethyl succinate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, produced by Streptomyces strains	1051	1264-62-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: erythromycin ethylsuccinate erythromycin ethyl succinate anamycin arpimycin eritrocina erythrocin ethyl succinate	A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Molecular weight: 862.06 Formula: C43H75NO16 CLOGP: 3.25 LIPINSKI: 2 HAC: 17 HDO: 4 TPSA: 226.28 ALOGS: -3.76 ROTB: 14 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

erythromycin ethylsuccinate
erythromycin ethyl succinate
anamycin
arpimycin
eritrocina
erythrocin ethyl succinate

A macrolide antibiotic, produced by Streptomyces erythreus. This compound is an ester of erythromycin base and succinic acid. It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.

Molecular weight: 862.06
Formula: C43H75NO16
CLOGP: 3.25
LIPINSKI: 2
HAC: 17
HDO: 4
TPSA: 226.28
ALOGS: -3.76
ROTB: 14

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
April 2, 1965	FDA	ARBOR PHARMS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	4711.90	12.77	2135	17073	248875	50337041
International normalised ratio fluctuation	180.68	12.77	56	19152	2134	50583782
Bloody discharge	118.21	12.77	35	19173	1139	50584777
Lyme disease	88.09	12.77	34	19174	2509	50583407
Seronegative arthritis	87.57	12.77	32	19176	2029	50583887
Exposure during pregnancy	66.72	12.77	144	19064	120871	50465045
Anaphylactic reaction	62.24	12.77	89	19119	53966	50531950
Wheezing	51.66	12.77	88	19120	61959	50523957
Faecal volume decreased	51.50	12.77	12	19196	148	50585768
Dislocation of vertebra	49.66	12.77	24	19184	3063	50582853
Rash	49.49	12.77	309	18899	437162	50148754
Drug interaction	48.36	12.77	176	19032	199445	50386471
Vomiting	47.56	12.77	318	18890	460440	50125476
Amniotic cavity infection	41.89	12.77	16	19192	1147	50584769
Pneumococcal infection	40.24	12.77	12	19196	400	50585516
Umbilical erythema	36.62	12.77	8	19200	72	50585844
Vertigo positional	35.85	12.77	18	19190	2493	50583423
Abortion spontaneous	34.43	12.77	59	19149	41713	50544203
Completed suicide	33.60	12.77	5	19203	131884	50454032
Purpura senile	33.24	12.77	11	19197	518	50585398
Death neonatal	32.73	12.77	9	19199	223	50585693
Necrosis ischaemic	32.44	12.77	12	19196	787	50585129
Drug intolerance	31.39	12.77	165	19043	218939	50366977
Caesarean section	31.30	12.77	34	19174	15605	50570311
Spondylitis	31.06	12.77	17	19191	2808	50583108
Tarsal tunnel syndrome	29.10	12.77	10	19198	529	50585387
Ototoxicity	28.44	12.77	12	19196	1115	50584801
Death	27.53	12.77	51	19157	325328	50260588
Pain	27.40	12.77	120	19088	578783	50007133
Mass excision	26.99	12.77	8	19200	261	50585655
Bronchial obstruction	26.88	12.77	12	19196	1278	50584638
Serum sickness-like reaction	26.45	12.77	9	19199	462	50585454
Fall	26.18	12.77	55	19153	334877	50251039
Drug tolerance decreased	25.85	12.77	24	19184	9136	50576780
Beta haemolytic streptococcal infection	25.78	12.77	13	19195	1817	50584099
Wound infection	25.34	12.77	27	19181	12121	50573795
Premature baby	25.34	12.77	33	19175	18304	50567612
Lip swelling	24.54	12.77	38	19170	24698	50561218
Pneumonia streptococcal	24.20	12.77	12	19196	1619	50584297
Breast cancer stage III	23.69	12.77	15	19193	3241	50582675
Spinal fusion surgery	23.22	12.77	16	19192	3979	50581937
Adjustment disorder with depressed mood	23.10	12.77	14	19194	2800	50583116
Resorption bone increased	22.99	12.77	10	19198	1001	50584915
Therapeutic product effect incomplete	22.37	12.77	81	19127	91434	50494482
Infection	21.24	12.77	125	19083	172829	50413087
Vestibular disorder	20.82	12.77	10	19198	1259	50584657
Abdominal pain upper	20.78	12.77	117	19091	159192	50426724
Mucous stools	20.19	12.77	13	19195	2889	50583027
Oligohydramnios	20.09	12.77	17	19191	5733	50580183
Premature rupture of membranes	19.07	12.77	15	19193	4565	50581351
Corneal neovascularisation	18.79	12.77	5	19203	109	50585807
Corneal perforation	18.70	12.77	7	19201	475	50585441
Pharyngeal oedema	18.67	12.77	24	19184	13141	50572775
Urticaria	18.13	12.77	97	19111	129464	50456452
Morbid thoughts	17.90	12.77	7	19201	535	50585381
Stevens-Johnson syndrome	16.98	12.77	30	19178	21722	50564194
Neutropenia	16.61	12.77	19	19189	147946	50437970
Infantile haemangioma	16.57	12.77	4	19204	58	50585858
Stomatitis	16.42	12.77	9	19199	101335	50484581
Starvation ketoacidosis	16.14	12.77	4	19204	65	50585851
Alopecia	16.14	12.77	44	19164	245003	50340913
Drug ineffective	16.13	12.77	217	18991	819116	49766800
Anal candidiasis	15.81	12.77	3	19205	12	50585904
Nasopharyngitis	15.63	12.77	31	19177	192896	50393020
Stenotrophomonas infection	15.52	12.77	9	19199	1660	50584256
Prescribed overdose	15.28	12.77	23	19185	14577	50571339
Premature delivery	15.17	12.77	30	19178	23633	50562283
Anaemia	14.70	12.77	48	19160	252408	50333508
Ergot poisoning	14.63	12.77	4	19204	97	50585819
Cardiac arrest neonatal	14.63	12.77	4	19204	97	50585819
Type 2 diabetes mellitus	14.63	12.77	37	19171	34338	50551578
Dysphoria	14.43	12.77	13	19195	4761	50581155
Product packaging issue	14.01	12.77	7	19201	960	50584956
Febrile neutropenia	13.99	12.77	10	19198	97657	50488259
Hypersensitivity	13.60	12.77	133	19075	215028	50370888
Dermatitis allergic	13.26	12.77	20	19188	12700	50573216
Blepharitis	13.25	12.77	9	19199	2186	50583730
Walking aid user	12.89	12.77	14	19194	6419	50579497
Renal impairment neonatal	12.80	12.77	3	19205	38	50585878
Maternal exposure during pregnancy	12.79	12.77	104	19104	159674	50426242

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	472.84	14.86	267	7585	68139	29498536
Hyphaema	75.93	14.86	19	7833	469	29566206
Toxic epidermal necrolysis	64.97	14.86	47	7805	18106	29548569
Product packaging issue	64.13	14.86	17	7835	530	29566145
Drug interaction	63.99	14.86	153	7699	197232	29369443
Dystonia	46.14	14.86	30	7822	9719	29556956
Acute generalised exanthematous pustulosis	41.58	14.86	23	7829	5560	29561115
Stupor	40.48	14.86	18	7834	2726	29563949
Premature baby	38.74	14.86	34	7818	17246	29549429
Rhabdomyolysis	36.36	14.86	61	7791	60747	29505928
Obstruction gastric	35.64	14.86	12	7840	858	29565817
Coagulation time prolonged	35.44	14.86	13	7839	1197	29565478
Intraocular pressure increased	33.67	14.86	19	7833	4770	29561905
Brain oedema	33.49	14.86	27	7825	12193	29554482
Pyloric stenosis	33.34	14.86	11	7841	739	29565936
Foetal death	31.87	14.86	8	7844	200	29566475
Product dispensing error	31.30	14.86	19	7833	5461	29561214
Eye pain	30.47	14.86	25	7827	11570	29555105
Deafness bilateral	30.33	14.86	11	7841	980	29565695
Ototoxicity	28.78	14.86	12	7840	1553	29565122
Low birth weight baby	28.04	14.86	19	7833	6589	29560086
Learning disorder	26.35	14.86	10	7842	1012	29565663
Foetal arrhythmia	26.32	14.86	6	7846	98	29566577
Oligohydramnios	24.12	14.86	7	7845	306	29566369
Oculogyric crisis	23.57	14.86	10	7842	1351	29565324
Caesarean section	23.29	14.86	11	7841	1912	29564763
Onychophagia	23.07	14.86	5	7847	64	29566611
Pathogen resistance	22.38	14.86	18	7834	8098	29558577
Respiratory acidosis	22.16	14.86	14	7838	4314	29562361
Potentiating drug interaction	21.84	14.86	14	7838	4424	29562251
Sepsis neonatal	21.12	14.86	6	7846	243	29566432
Torsade de pointes	21.02	14.86	16	7836	6645	29560030
Myasthenia gravis crisis	21.02	14.86	7	7845	484	29566191
Vasculitic rash	20.67	14.86	8	7844	853	29565822
Accidental exposure to product	19.88	14.86	19	7833	10734	29555941
Hepatic necrosis	19.51	14.86	12	7840	3530	29563145
Ischaemic hepatitis	19.19	14.86	9	7843	1539	29565136
Megacolon	18.88	14.86	9	7843	1596	29565079
Myoglobinuria	18.36	14.86	7	7845	717	29565958
Stevens-Johnson syndrome	17.91	14.86	22	7830	16475	29550200
Measles	17.91	14.86	5	7847	190	29566485
Neonatal disorder	17.66	14.86	7	7845	796	29565879
Cardio-respiratory arrest neonatal	17.55	14.86	3	7849	9	29566666
Tricuspid valve disease	17.38	14.86	5	7847	212	29566463
Swelling face	17.21	14.86	24	7828	20326	29546349
Akinesia	17.05	14.86	9	7843	1981	29564694
Brain herniation	16.75	14.86	11	7841	3622	29563053
Hepatic failure	16.71	14.86	30	7822	31482	29535193
Visual acuity reduced	16.41	14.86	20	7832	14856	29551819
Pupillary disorder	16.30	14.86	5	7847	265	29566410
Exposure during pregnancy	15.60	14.86	15	7837	8539	29558136
Accidental overdose	15.25	14.86	21	7831	17572	29549103
Skin wrinkling	15.25	14.86	5	7847	329	29566346

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	3217.82	12.29	1564	20134	236251	64240783
International normalised ratio fluctuation	174.75	12.29	57	21641	2904	64474130
Bloody discharge	118.71	12.29	36	21662	1441	64475593
Drug interaction	106.01	12.29	314	21384	361769	64115265
Lyme disease	93.80	12.29	34	21664	2381	64474653
Product packaging issue	79.25	12.29	24	21674	956	64476078
Seronegative arthritis	68.49	12.29	28	21670	2715	64474319
Hyphaema	65.91	12.29	19	21679	636	64476398
Dislocation of vertebra	49.04	12.29	23	21675	3101	64473933
Ototoxicity	48.86	12.29	22	21676	2701	64474333
Wheezing	48.86	12.29	93	21605	80486	64396548
Toxic epidermal necrolysis	48.24	12.29	61	21637	37105	64439929
Anaphylactic reaction	46.34	12.29	83	21615	68581	64408453
Rash	39.76	12.29	277	21421	458272	64018762
Exposure during pregnancy	39.13	12.29	83	21615	77592	64399442
Pneumococcal infection	37.35	12.29	13	21685	808	64476226
Stevens-Johnson syndrome	36.43	12.29	51	21647	34198	64442836
Maternal exposure during pregnancy	35.72	12.29	91	21607	95793	64381241
Stupor	34.87	12.29	23	21675	6012	64471022
Drug intolerance	34.63	12.29	140	21558	187852	64289182
Drug abuse	33.48	12.29	3	21695	132371	64344663
Vertigo positional	32.51	12.29	17	21681	2894	64474140
Drug tolerance decreased	31.79	12.29	23	21675	6975	64470059
Caesarean section	31.78	12.29	28	21670	11246	64465788
Necrosis ischaemic	31.43	12.29	12	21686	971	64476063
Febrile neutropenia	31.27	12.29	12	21686	187645	64289389
Tarsal tunnel syndrome	30.92	12.29	10	21688	495	64476539
Purpura senile	30.81	12.29	10	21688	501	64476533
Learning disorder	30.16	12.29	10	21688	536	64476498
Completed suicide	29	12.29	20	21678	224394	64252640
Intraocular pressure increased	28.30	12.29	23	21675	8279	64468755
Coagulation time prolonged	28.23	12.29	14	21684	2132	64474902
Deafness bilateral	26.96	12.29	13	21685	1863	64475171
Breast cancer stage III	26.95	12.29	15	21683	2890	64474144
Pneumonia streptococcal	26.88	12.29	14	21684	2364	64474670
Beta haemolytic streptococcal infection	26.85	12.29	13	21685	1881	64475153
Respiratory acidosis	26.83	12.29	24	21674	9831	64467203
Acute generalised exanthematous pustulosis	26.54	12.29	28	21670	14030	64463004
Adjustment disorder with depressed mood	26.44	12.29	14	21684	2443	64474591
Anaemia	26.32	12.29	55	21643	378625	64098409
Serum sickness-like reaction	26.15	12.29	9	21689	541	64476493
Infection	25.96	12.29	127	21571	184753	64292281
Death	25.91	12.29	80	21618	482625	63994409
Product dispensing error	25.62	12.29	25	21673	11425	64465609
Torsade de pointes	24.94	12.29	30	21668	17333	64459701
Vomiting	24.94	12.29	289	21409	550828	63926206
Lip swelling	24.70	12.29	41	21657	31866	64445168
Spinal fusion surgery	23.77	12.29	15	21683	3636	64473398
Wound infection	23.54	12.29	27	21671	14837	64462197
Spondylitis	23.47	12.29	14	21684	3072	64473962
Oculogyric crisis	23.26	12.29	13	21685	2525	64474509
Mass excision	22.85	12.29	7	21691	290	64476744
Resorption bone increased	22.76	12.29	10	21688	1158	64475876
Corneal neovascularisation	22.68	12.29	6	21692	145	64476889
Pharyngeal oedema	22.58	12.29	27	21671	15504	64461530
Therapeutic product effect incomplete	22.26	12.29	81	21617	103401	64373633
Bronchial obstruction	21.32	12.29	12	21686	2362	64474672
Oligohydramnios	20.75	12.29	13	21685	3111	64473923
Neutropenia	20.04	12.29	31	21667	239593	64237441
Dystonia	19.92	12.29	28	21670	18837	64458197
Dermatitis allergic	19.92	12.29	25	21673	15084	64461950
Fall	19.68	12.29	73	21625	416753	64060281
Swelling face	18.84	12.29	53	21645	59113	64417921
Premature rupture of membranes	18.61	12.29	13	21685	3731	64473303
Pathogen resistance	18.56	12.29	22	21676	12521	64464513
Eye pain	18.54	12.29	36	21662	31589	64445445
Ergot poisoning	18.30	12.29	5	21693	137	64476897
Malignant neoplasm progression	17.53	12.29	8	21690	112863	64364171
Platelet count decreased	16.77	12.29	19	21679	167692	64309342
Morbid thoughts	16.73	12.29	7	21691	719	64476315
Rhabdomyolysis	16.62	12.29	68	21630	91658	64385376
Brain oedema	16.60	12.29	28	21670	22047	64454987
Vestibular disorder	16.40	12.29	10	21688	2283	64474751
Hypotension	15.91	12.29	70	21628	380904	64096130
Premature delivery	15.91	12.29	25	21673	18564	64458470
Abdominal pain upper	15.85	12.29	107	21591	174923	64302111
Haemoglobin decreased	15.59	12.29	26	21672	195037	64281997
Live birth	15.51	12.29	19	21679	11185	64465849
Potentiating drug interaction	15.47	12.29	16	21682	7836	64469198
Anal candidiasis	15.46	12.29	3	21695	16	64477018
Myasthenia gravis crisis	15.41	12.29	7	21691	877	64476157
Asthenia	15.36	12.29	83	21615	427961	64049073
Urticaria	15.14	12.29	93	21605	147224	64329810
Confusional state	14.91	12.29	42	21656	261102	64215932
Grip strength decreased	14.82	12.29	19	21679	11705	64465329
Walking aid user	14.59	12.29	14	21684	6267	64470767
Myoglobinuria	14.59	12.29	7	21691	993	64476041
Type 2 diabetes mellitus	14.48	12.29	34	21664	33986	64443048
Starvation ketoacidosis	14.46	12.29	4	21694	115	64476919
Cardiac arrest neonatal	13.81	12.29	3	21695	30	64477004
Corneal perforation	13.80	12.29	6	21692	678	64476356
Cardio-respiratory arrest	13.75	12.29	8	21690	98385	64378649
Ulcerative keratitis	13.66	12.29	10	21688	3087	64473947
Hyponatraemia	13.57	12.29	18	21680	148321	64328713
Tricuspid valve disease	13.31	12.29	5	21693	387	64476647
Prescribed overdose	12.97	12.29	24	21674	20307	64456727
Abdominal rigidity	12.77	12.29	9	21689	2618	64474416
Drug resistance	12.73	12.29	33	21665	35069	64441965
Pupillary disorder	12.60	12.29	5	21693	449	64476585
Dysphoria	12.57	12.29	11	21687	4377	64472657
Documented hypersensitivity to administered product	12.56	12.29	6	21692	842	64476192
Vasculitic rash	12.51	12.29	8	21690	1983	64475051

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA CS	M0028311	Macrolides
FDA PE	N0000009982	Decreased Sebaceous Gland Activity
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D011500	Protein Synthesis Inhibitors
FDA EPC	N0000175877	Macrolide
FDA EPC	N0000175935	Macrolide Antimicrobial

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Meningitis	indication	7180009	DOID:9471
Bacterial septicemia	indication	10001005	DOID:0040085
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Bacterial pneumonia	indication	53084003	DOID:874
Urinary tract infectious disease	indication	68566005
Hepatic coma	indication	72836002	DOID:12550
Cholangitis	indication	82403002	DOID:9446
Infection of bone	indication	111253001
Infectious disease of abdomen	indication	128070006
Infectious disorder of joint	indication	363162000
Preoperative Bowel Preparation	indication
Burn Wound Infections	indication
Acute tuberculosis	off-label use	25629007
Pulmonary tuberculosis	off-label use	154283005	DOID:2957
Hypocalcemia	contraindication	5291005
Parkinsonism	contraindication	32798002
Dehydration	contraindication	34095006
Tinnitus	contraindication	60862001
Kidney disease	contraindication	90708001	DOID:557
Myasthenia gravis	contraindication	91637004	DOID:437
Pregnancy, function	contraindication	289908002
Vertigo	contraindication	399153001
Infant Botulism	contraindication
Disorder of the 8th Cranial Nerve	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.61	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
4017592	VUID
N0000145973	NUI
4017592	VANDF
4017594	VANDF
C0014810	UMLSCUI
CHEBI:31555	CHEBI
CHEBI:42355	CHEBI
CHEMBL1200688	ChEMBL_ID
D015643	MESH_DESCRIPTOR_UI
1014KSJ86F	UNII
443953	PUBCHEM_CID
12560	PUBCHEM_CID
DB00199	DRUGBANK_ID
151373	RXNORM
33314	MMSL
42396	MMSL
4543	MMSL
4675	MMSL
4677	MMSL
4799	MMSL
72164	MMSL
d00046	MMSL
002755	NDDF
002757	NDDF
12578001	SNOMEDCT_US
30427009	SNOMEDCT_US
372694001	SNOMEDCT_US
C0014806	UMLSCUI
39	INN_ID
D004917	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL	HUMAN PRESCRIPTION DRUG LABEL	2	21695-690	GRANULE, FOR SUSPENSION	200 mg	ORAL	ANDA	26 sections
E.E.S 400	HUMAN PRESCRIPTION DRUG LABEL	1	24338-100	TABLET	400 mg	ORAL	ANDA	27 sections
ERYTHROMYCIN ETHYLSUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	24338-110	TABLET	400 mg	ORAL	ANDA	26 sections
Ery-Ped	HUMAN PRESCRIPTION DRUG LABEL	1	24338-130	SUSPENSION	400 mg	ORAL	NDA	27 sections
Ery-Ped	HUMAN PRESCRIPTION DRUG LABEL	1	24338-132	SUSPENSION	200 mg	ORAL	NDA	27 sections
E.E.S	HUMAN PRESCRIPTION DRUG LABEL	1	24338-134	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
E.E.S	HUMAN PRESCRIPTION DRUG LABEL	1	24338-136	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
ERYTHROMYCIN ETHYLSUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	52536-130	SUSPENSION	400 mg	ORAL	NDA	27 sections
ERYTHROMYCIN ETHYLSUCCINATE	HUMAN PRESCRIPTION DRUG LABEL	1	52536-132	SUSPENSION	200 mg	ORAL	NDA	27 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	52536-134	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	28 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	52536-136	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	28 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	54868-0018	TABLET	400 mg	ORAL	ANDA	13 sections
ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL	HUMAN PRESCRIPTION DRUG LABEL	2	54868-0971	GRANULE, FOR SUSPENSION	200 mg	ORAL	ANDA	26 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-440	GRANULE, FOR SUSPENSION	200 mg	ORAL	ANDA	23 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-440	GRANULE, FOR SUSPENSION	200 mg	ORAL	ANDA	23 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-630	GRANULE, FOR SUSPENSION	200 mg	ORAL	ANDA	22 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	62559-631	GRANULE, FOR SUSPENSION	400 mg	ORAL	ANDA	22 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2500	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2500	GRANULE, FOR SUSPENSION	200 mg	ORAL	NDA	27 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1503	SUSPENSION	200 mg	ORAL	ANDA	19 sections
Erythromycin Ethylsuccinate	HUMAN PRESCRIPTION DRUG LABEL	1	69238-1504	SUSPENSION	400 mg	ORAL	ANDA	19 sections